Want to see IN:INDSWFTLAB full AI Analyst Report?

Ind-Swift Laboratories Ltd. (INDSWFTLAB) Price & Analysis

0 Followers

INDSWFTLAB Stock Chart & Stats

₹227.00

₹12.42(5.46%)

At close: Jul 27 4:00 PM EDT

₹227.00

₹12.42(5.46%)

Day’s Range― - ―

52-Week Range₹87.00 - ₹424.55

Previous CloseN/A

Volume478.31K

Average Volume (3M)46.79K

Market Cap

₹30.65B

Enterprise Value₹7.06B

Total Cash (Recent Filing)₹4.42B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)50.2

Beta0.79

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.14%

Share Statistics

EPS (TTM)6.82

Shares Outstanding86,961,555

10 Day Avg. Volume26,356

30 Day Avg. Volume46,786

Financial Highlights & Ratios

PEG Ratio-0.31

Price to Book (P/B)0.79

Price to Sales (P/S)1.71

P/FCF Ratio-10.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved Balance SheetLower leverage and a steadily expanding equity base improve the company’s ability to absorb operating volatility and finance required pharmaceutical activity. This strengthens balance-sheet resilience and may preserve strategic flexibility, although the sharp historical shifts warrant monitoring.

Established API Supply RoleAn API and intermediate manufacturing model places the company within the supply chain for finished medicines, with sales to domestic and export markets. That operating focus provides a defined pharmaceutical niche and access to demand from formulation manufacturers across geographies.

Demonstrated ProfitabilityStrong net income in 2023–2025 shows the business has demonstrated an ability to generate profits after earlier losses. That record provides evidence of underlying earnings capacity, even though the latest year’s weaker operating results make sustainability less certain.

Bears Say

Persistent Cash BurnNegative operating cash flow in 2024–2026 and negative free cash flow in each of the last three years indicate that reported earnings are not converting into liquidity. Continued cash burn can constrain reinvestment, debt reduction, and resilience through weaker trading.

Recent Revenue ContractionRevenue contracted sharply in 2025 and again in 2026, with annual revenue down about 22% in the latest year. A sustained top-line decline can weaken operating momentum and reduce the company’s ability to fund expansion or absorb fixed costs internally.

Volatile Operating ProfitabilityProfitability has been volatile: the company moved from losses to strong profits, then recorded much lower EBIT and gross profit in 2026 despite positive net income. This divergence makes earnings quality and operating stability less predictable.

Ind-Swift Laboratories Ltd. News

Ind-Swift Laboratories schedules virtual investor meet with Arihant Capital

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has provided an update. Ind-Swift Laboratories Ltd. has scheduled a virtual group...

29d ago

Ind-Swift Laboratories Publishes Notices for 31st AGM and Annual Report Access

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has provided an announcement. Ind-Swift Laboratories Ltd., a listed Indian pharmaceutical company,...

2M ago

Ind-Swift Laboratories Sets Q1 FY27 Earnings Call for August 17

The latest update is out from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ). Ind-Swift Laboratories Ltd. has scheduled an...

2M ago

Ind-Swift Labs Revises EGM Notice on Preferential Issue for Expansion

An announcement from Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) is now available. Ind-Swift Laboratories Ltd. has issued a...

3M ago

Ind-Swift Laboratories to Hold Extraordinary General Meeting via Video Conference on August 5

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has provided an announcement. Ind-Swift Laboratories Ltd. has informed shareholders that it...

3M ago

Ind-Swift Laboratories Seeks Shareholder Nod for Major Leadership Restructuring via Postal Ballot

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an announcement. Ind-Swift Laboratories Ltd. has launched a postal ballot...

7M ago

Ind-Swift Labs Retains ₹19.66 Crore as 6.5 Million Warrants Lapse

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has issued an announcement. Ind-Swift Laboratories has announced that 6.5 million fully...

8M ago

Ind-Swift Labs Files CARE Monitoring Report on Rs 314.6 Crore Preferential Issue

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has shared an announcement. Ind-Swift Laboratories Ltd. has disclosed that CARE Ratings...

9M ago

Ind-Swift Laboratories Closes Trading Window Ahead of Q3 FY2025 Results

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) just unveiled an update. Ind-Swift Laboratories Ltd. has announced the closure of...

10M ago

Ind-Swift Laboratories Completes Intra-Promoter Transmission of 232,057 Shares

Ind-Swift Laboratories Ltd. ( ($IN:INDSWFTLAB) ) has issued an update. Ind-Swift Laboratories Ltd. has informed the stock exchanges...

10M ago

INDSWFTLAB FAQ

What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?

Ind-Swift Laboratories Ltd. lowest stock price was ₹87.00 and its highest was ₹424.55 in the past 12 months.

What is Ind-Swift Laboratories Ltd.’s market cap?

Ind-Swift Laboratories Ltd.’s market cap is ₹30.65B.

When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?

Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.

How were Ind-Swift Laboratories Ltd.’s earnings last quarter?

Ind-Swift Laboratories Ltd. released its earnings results on Aug 12, 2026. The company reported ₹2.843 earnings per share for the quarter.

Is Ind-Swift Laboratories Ltd. overvalued?

According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ind-Swift Laboratories Ltd. pay dividends?

Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of 1.14%. See more information on Ind-Swift Laboratories Ltd. dividends here

What is Ind-Swift Laboratories Ltd.’s EPS estimate?

Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ind-Swift Laboratories Ltd. have?

Ind-Swift Laboratories Ltd. has 86,961,555 shares outstanding.

What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?

Ind-Swift Laboratories Ltd. reported an EPS of ₹2.843 in its last earnings report. Following the earnings report the stock price went up 5.308%.

Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:INDSWFTLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ind-Swift Laboratories Ltd.

Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.